compared it with those of ciprofloxacin, sparfloxacin and levofloxacin.
Introduction
Selected fluoroquinolones have excellent in-vitro activity against Neisseria gonorrhoeae, including strains with plasmid-mediated penicillin resistance, plasmid-mediated tetracycline resistance and chromosomally mediated resistance to penicillin and/or tetracycline. These agents have been demonstrated to be highly effective in curing uncomplicated gonorrhoea. Recently, however, we have found the emergence of clinical strains of N. gonorrhoeae with decreased susceptibility to fluoroquinolones and have observed fluoroquinolone treatment failures in gonorrhoea.
Several mechanisms of quinolone resistance have been identified and characterized in N. gonorrhoeae strains with decreased susceptibility to quinolones. In laboratory mutant strains, alterations of the GyrA subunit of DNA gyrase play a primary role in conferring quinolone resistance in N. gonorrhoeae. 1 Alterations in the ParC subunit of DNA topoisomerase IV are responsible for an increase in resistance to fluoroquinolones. 1 In clinical isolates of N. gonorrhoeae, we have demonstrated that alterations in GyrA are associated with high-level resistance to nalidixic acid and with decreased susceptibility to fluoroquinolones, and that the accumulation of amino acid changes in GyrA and the simultaneous presence of ParC alterations may lead to higher-level resistance to fluoroquinolones. 2 For the clinical application of newly developed fluoroquinolones for the treatment of gonorrhoea, they must be more active against N. gonorrhoeae strains, especially those harbouring quinolone-resistance-associated alterations in GyrA and ParC.
HSR-903 is a novel fluorinated quinolone currently in the clinical phase of investigation. This compound has the 6-fluorine generally found on currently available quinolones and contains an amino group at position 5, an aminopyrrolidinyl group at position 7 and a methyl group at position 8. Although initial susceptibility studies have shown that HSR-903 has a broad antimicrobial spectrum, 3, 4 its activity against N. gonorrhoeae has not been assessed. In this study, we determined the in-vitro activity of HSR-903 against N. gonorrhoeae clinical isolates, including those harbouring alterations in GyrA and ParC associated with quinolone resistance, and 
Materials and methods
Fifty-one clinical strains of N. gonorrhoeae were isolated between 1991 and 1993 from Japanese patients with gonococcal urethritis. In one of our previous studies, all strains had been examined for mutations in the region corresponding to the quinolone-resistance-determining region of the Escherichia coli gyrA gene and the analogous region of the parC gene. 2 Of the 51 strains, 11 had mutations resulting in alterations in both GyrA and ParC, 19 had mutations generating amino acid changes only in GyrA, and the remaining 21 strains had no mutations in either the gyrA or parC gene.
In this study, antimicrobial susceptibilities of the N. gonorrhoeae isolates to HSR-903 (Hokuriku Seiyaku Co. Ltd, Fukui, Japan), ciprofloxacin, sparfloxacin and levofloxacin were tested using an agar dilution method. MICs of these fluoroquinolones were determined on GCII agar base medium (Becton Dickinson, Cockeysville, MD, USA) supplemented with 1% IsoVitaleX (Becton Dickinson) and containing serial two-fold dilutions of each agent in accordance with the method of the National Committee for Clinical Laboratory Standards. 5 Media were inoculated with 10 4 cfu and incubated for 24 h at 37°C in CO 2 -enhanced (4-10%) atmosphere using GasPak Plus (Becton Dickinson). The MIC was defined as the lowest concentration inhibiting growth to 1 cfu.
Results
In this study, 51 isolates of N. gonorrhoeae were assigned to one of three categories based on the presence or absence of alterations in GyrA and ParC. 2 The Table summarizes 
Discussion
Recently, single 500 mg doses of ciprofloxacin have been recommended as the primary therapy for uncomplicated gonorrhoea. 6 However, ciprofloxacin treatment failures have been observed. 7, 8 The failures occurring with these higher doses correlated with ciprofloxacin MICs for the causative organisms ranging from 1.0 mg/L to 16.0 mg/L. 7, 8 These strains would correspond to those harbouring alterations in both GyrA and ParC among the isolates tested in our present study. Although HSR-903 had lower antimicrobial activity against these strains, as did ciprofloxacin, sparfloxacin and levofloxacin, its MICs for the strains still more potent activity than the other fluoroquinolones. HSR-903 was also more active than ciprofloxacin and levofloxacin and marginally better than sparfloxacin against moderately fluoroquinolone-resistant strains with alterations in GyrA alone and quinolone-susceptible strains without alterations in GyrA or ParC. Of all the fluoroquinolones tested in this study, HSR-903 exhibited the most potent activity against clinical isolates of N. gonorrhoeae, including those harbouring quinolone-resistanceassociated alterations in GyrA and ParC. The pharmacokinetics of HSR-903 have been studied in humans. In a single-dose study, the concentrations in serum reached a peak between 1 and 3 h, and the peak concentrations were 0.86 mg/L and 1.75 mg/L at doses of 200 mg and 400 mg, respectively. The elimination half-life of HSR-903 was 18 h, and this was independent of the dose. 9 In contrast, in a pharmacokinetic analysis of ciprofloxacin, 10 the peak concentrations of ciprofloxacin were 1.37 and 2.23 mg/L, and its elimination half-lives were 2.76 h and 5.71 h at single doses of 200 mg and 400 mg, respectively. The peak serum concentrations of HSR-903 were lower than those of ciprofloxacin, but HSR-903 had a much longer half-life. 9, 10 Thus, the AUC 0-∞ values of HSR-903 are three-fold and two-fold greater than those of ciprofloxacin at the single doses of 200 mg and 400 mg, respectively. 9, 10 Although clinical applications of HSR-903 for the treatment of gonorrhoea depend on further clinical efficacy studies, our present results, together with the findings from previous pharmacokinetic studies, suggest that HSR-903 may be a useful and suitable agent for the single-dose treatment of gonorrhoea because of its potent in-vitro antimicrobial activity against N. gonorrhoeae strains, including quinolone-resistant strains, and its favourable pharmacokinetic behaviour.
